The therapeutic and diagnostic efficiency of engineered small proteins and peptides is hampered by short in vivo serum half-life. Thus, strategies to tailor their serum persistence are needed. Such strategies include specialized drug delivery systems, covalent binding to polymers, and non-covalent binding to human serum albumin.
Albumin binding is the most convenient and safest of those strategies. However, optimization of albumin binding has been hampered by technical challenges arising from chemical properties of the peptides. Frequently, they resist diffusion across dialysis or ultrafiltration membranes, so that standard devices cannot be used to measure albumin and plasma protein binding.
Without being able to measure albumin binding, it is difficult to optimize this attribute. Also, peptides frequently stick to plastic laboratory equipment unless special solubility enhancing buffer systems and plasma help to keep them in solution. In the past, these challenges limited the otherwise convenient and safe approach of optimizing peptide drugs’ albumin binding to extend their half-life.
In this webinar, we review the currently used approaches to manage the half-life of peptide drugs and present a new technique that facilitates accurate and straightforward albumin and plasma protein binding measurements of peptide drugs.
Dr. Hinnerk Boriss,
CEO
Hinnerk is CEO and owner of Sovicell GmbH. He’s been working in drug discovery for over 10 years and has over 25 years of experience science at the interface of math and biology and developed several clinical diagnostic tests and biochemical assays. His specialty is assay development through a combination of mathematical modeling of assay conditions and wet-lab validation. He received his education in biochemistry, theoretical physics and biostatistics from the University of Göttingen, Germany, the University of California Davis, the Max Planck Institute for Limnology and Stanford University.
- Strategies to extend the half-life of peptide drugs
- PH dependence of albumin binding and its consequence in RcRn Receptor recycling
- Use of competitive binding models for measuring dissociation constants
- Technical details and handling of a novel technique for measuring plasma and albumin binding of peptide drugs
- Group Leaders
- Lab Heads
- Scientist
- Technology Managers
- Innovation Manager
- Head of Preclinical R&D
